Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ARIA Ariad Pharmaceuticals (ARIA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Ariad Pharmaceuticals Stock (NASDAQ:ARIA) 30 days 90 days 365 days Advanced Chart Ad Porter & CompanyI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. And something BIG is about to happen.“The Final Frontier” of tech is here, click now to watch this exclusive video Get Ariad Pharmaceuticals alerts:Sign Up Key Stats Today's Range$23.99▼$23.9950-Day Range N/A52-Week Range$4.67▼$23.99VolumeN/AAverage Volume15.70 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).Read More… Receive ARIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ariad Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARIA Stock News HeadlinesResolution Therapeutics Announces £63.5 Million Series B Financing and Chair AppointmentOctober 3, 2024 | finance.yahoo.comSolu Therapeutics Strengthens Leadership Team with Appointment of Sergio Santillana, MD, as Chief Medical OfficerSeptember 10, 2024 | finance.yahoo.com$19 for a FULL YEAR of stock picks?!We're offering you the chance to subscribe to Behind the Markets for an ENTIRE YEAR for just $19. But why? Because there is a very small window of time... as little as 25 days from now... That will change the market forever.December 26, 2024 | Behind the Markets (Ad)Affimed Appoints Shawn Leland As New CEOSeptember 3, 2024 | markets.businessinsider.comTerns Pharmaceuticals Finance Chief Vignola LeavingJuly 29, 2024 | marketwatch.comIDRx Appoints David P. Kerstein, M.D., as Chief Medical OfficerMarch 27, 2024 | finance.yahoo.comIDRx Strengthens Executive Team with Appointments of Tim Clackson, Ph.D., as CEO and Brad Dahms as CFO and CBOMarch 12, 2024 | finance.yahoo.comWhat Is Donanemab? Eli Lilly’s Alzheimer’s Drug Gets Delayed Decision From FDAMarch 8, 2024 | msn.comSee More Headlines ARIA Stock Analysis - Frequently Asked Questions How were Ariad Pharmaceuticals' earnings last quarter? Ariad Pharmaceuticals Inc (NASDAQ:ARIA) issued its quarterly earnings results on Thursday, July, 28th. The pharmaceutical company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.70. The business's revenue for the quarter was up 133.0% compared to the same quarter last year. What other stocks do shareholders of Ariad Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ariad Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Meta Platforms (META), Bristol-Myers Squibb (BMY), Twitter (TWTR), ACADIA Pharmaceuticals (ACAD), Ford Motor (F) and Gilead Sciences (GILD). Company Calendar Last Earnings7/28/2016Today12/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:ARIA CUSIP04033A10 CIK884731 Webwww.ariad.com Phone+1-617-4940400FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report This page (NASDAQ:ARIA) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredBuy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ariad Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ariad Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.